SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TOSHI

TOSHI is trending as the community speculates on upcoming AI-driven utility and ecosystem expansions, with many investors actively loading up on positions to lower their cost basis during current consolidation. Enthusiasts are highlighting the project's large holder count and long-term potential, maintaining a bullish outlook while awaiting a significant catalyst to drive the next breakout.

Curaleaf Holdings, Inc. operates as a holding company with interest in medical and wellness cannabis operations. It operates through the Domestic Operations and International Operations segments. The company was founded on November 13, 2014 and is headquartered in Stamford, CT.

Curaleaf Holdings Inc

Curaleaf investors are closely monitoring the DEA's upcoming administrative hearings on potential cannabis rescheduling, fueling speculation about the industry's legislative future. The community is actively debating the company's competitive advantages in international markets and its growth potential, while navigating concerns over recent corporate restructuring actions.

Nintendo Co., Ltd. engages in the development, manufacture, and sale of home entertainment products. Its entertainment products include portable and console game machines and software, trump cards and Karuta (Japanese-style playing cards), multinational consumer electronics, home console hardware such as Nintendo Wii, Nintendo DS, Nintendo 3DS, as well as software for handheld and home console gaming machines. The company was founded by Fusajiro Yamauchi on September 23, 1889 and is headquartered in Kyoto, Japan.

Nintendo Co. Ltd - ADR

Nintendo is seeing increased investor scrutiny as market participants weigh strong demand and high pre-order volume for the Switch 2 against concerns regarding rising component costs and the impact of broader economic headwinds. Community discussions remain polarized, with many analysts and long-term shareholders focusing on the company's powerful IP library and potential for margin expansion, while others express caution over the console's premium pricing and the sustainability of sales growth in a competitive environment.

Select Sector SPDR Trust (The) - State Street Health Care Select Sector SPDR ETF

Health Care Select Sector SPDR Fund

The Health Care Select Sector SPDR Fund ($XLV) is currently experiencing increased capital inflows as market participants rotate out of overextended technology and growth sectors into more defensive positions. Investors are closely monitoring the sector's technical breakout levels and individual constituents like Eli Lilly as they look for stability and durable demand in an uncertain macro environment.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors rotate into high-yield, defensive healthcare stocks amidst broader market volatility, while the company also continues to aggressively pursue oncology M&A to address long-term patent concerns. The community remains focused on Merck's strategic deal-making and its role as a stable anchor in portfolios currently shifting away from momentum-heavy sectors.

Sony Group Corp. engages in the development, design, manufacture, and sale of electronic equipment, instruments, devices, game consoles, and software for consumers, professionals and industrial markets. It operates through the following segments: Game and Network Services, Music, Pictures, Entertainment Technology & Services, Imaging and Sensing Solutions, Financial Services, and Others. The Game and Network Services segment deals with gaming machines, software and network services. The Music segment produces and publishes music and provides image media platforms. The Pictures segment handles film production, television program creation, and media networks. The Home Entertainment and Sound segment offers LCD televisions, home audio, Blu-ray Disc players and recorders, and memory-based portable audio devices. The Imaging and Sensing Solutions segment includes the image sensors business. The Financial Services segment manages the life insurance and non-life insurance operations and banking business. The Others segment consists of various operating activities, including the disc manufacturing and recording media businesses. The company was founded by Akio Morita and Masaru Ibuka on May 7, 1946 and is headquartered in Tokyo, Japan.

Sony Group Corporation - ADR

Sony Group Corporation

Sony is actively capturing investor attention as it undergoes a significant corporate transformation, headlined by the planned spin-off of its financial services division and ongoing strategic moves to streamline its core media and semiconductor operations. Market participants are keenly debating the balance between the firm's strong intellectual property and music streaming growth against potential headwinds from memory chip cost pressures and global supply chain volatility.

Dogelon Mars

Dogelon Mars continues to trend as investors debate its long-term potential, with community members actively comparing the project to other meme coins while calling for strategic token burns to boost visibility. Sentiment remains polarized between those hoping for a speculative breakout and those frustrated by historical price performance and a lack of clear development updates.

PepsiCo, Inc. engages in the manufacture, marketing, distribution, and sale of beverages, food, and snacks. It operates through the following business segments: PepsiCo Foods North America (PFNA), PepsiCo Beverages North America (PBNA), International Beverages Franchise (IB Franchise), Europe, Middle East and Africa (EMEA), Latin America Foods (LatAm Foods), and Asia Pacific Foods. The PFNA segment refers to the food businesses in the United States and Canada. The PBNA segment includes beverage businesses in the United States and Canada. The IB Franchise segment involves the international franchise beverage businesses, as well as the SodaStream business. The EMEA segment pertains to food businesses and beverage businesses with company-owned bottlers in Europe, the Middle East, and Africa. The LatAm Foods segment consists of food businesses in Latin America. The Asia Pacific Foods segment is associated in food businesses in Asia Pacific, including China, Australia and New Zealand, as well as India. The company was founded by Donald M. Kendall, Sr. and Herman W. Lay in 1965 and is headquartered in Purchase, NY.

PepsiCo Inc

PepsiCo is trending as investors weigh its defensive strengths and dividend growth against ongoing challenges in beverage volume and consumer pricing sensitivity. The community remains focused on potential strategic acquisitions, management's brand innovation efforts, and the stock's resilience relative to broader market volatility.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending as investors focus on rapid commercial scaling and the upcoming launches of Byooviz and Byqlovi, fueling bullish sentiment around the potential for long-term revenue growth. Community discussion is dominated by high conviction in the companys platform strategy and the belief that the stock is positioned for significant appreciation as recent sales force expansion and data momentum begin to materialize.

ProShares Trust II - ProShares Ultra VIX Short-Term Futures ETF 1.5x Shares

ProShares Ultra VIX Short-Term Futures ETF

Investors are closely monitoring volatility products like UVXY as market sentiment fluctuates between extreme optimism driven by AI infrastructure spending and mounting anxiety over geopolitical tensions. The community is sharply divided, with some traders actively shorting volatility amid record-high equity indices, while others maintain hedge positions in anticipation of a potential market correction linked to shifting macroeconomic conditions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year PR Newswire NEW YORK and TORONTO, June 26, 2026 Issued on behalf of Helus PharmaHelus Pharma...

FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

– APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment – – Phase 2 HLP003 data demonstrated long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale (“MADRS”) score compared to baseline at 12 months after two 16 mg […]
The post FNM News Break: Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress appeared first on Financial News Media.

Cybin (NASDAQ:HELP) Shares Up 2.7%  - Should You Buy?

Cybin (NASDAQ:HELP) Shares Up 2.7% - Should You Buy...

FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain

Equity

The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.

Cybin Inc. (NASDAQ:HELP) Given Average Recommendation of "Buy" by Brokerages

Shares of Cybin Inc. (NASDAQ:HELP - Get Free Report) have been assigned an average recommendation of "Buy" from the six analysts that are covering the firm, Marketbeat Ratings reports. Five analysts...

Cybin (NASDAQ:HELP) Now Covered by TD Cowen

TD Cowen assumed coverage on shares of Cybin in a research report on Monday. They set a "buy" rating and a $8.00 price objective on the stock...

Cybin (NASDAQ:HELP)  Shares Down 2.1%   - Time to Sell?

Cybin (NASDAQ:HELP) Trading Down 2.1% - Here's What Happened...

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions

CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions PR Newswire VANCOUVER, BC, March 9, 2026 Issued...

HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside

Jefferies highlighted the Phase 3 Approach trial for depression drug HLP003 as the next key catalyst for the stock.

Dow Futures Hold Ground After 800-Point Selloff As Oil Surge Hits Wall Street: Why MRVL, USO, COST, HELP Are Trending After-Hours

U.S. crude surged above $80 per barrel after a reported Iranian missile strike on an oil tanker.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$6.48
Prev Close	$6.02
Open	$5.90
Dividend Yield	N/A
50-Day Moving Average	$4.86
Beta	1.08
Avg. Volume	744,787.28
PE Ratio	-1.33

52-Week High	$9.83
52-Week Low	$3.76
Market Capitalization	$301.22M
EPS (Annual)	-$4.02
Price to Book	1.10
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

HELPHelus Pharma Inc.

Latest HELP News